Queensland company NuNerve has announced promising early results in a Phase 1 patient cohort of eight people with MND and 20 healthy volunteers who were dosed with its lead compound NUN-004 for six months. …
Potential Australian developed treatment for MND shows positive early trial results
December 9, 2024 Australian Biotech
Latest Video
New Stories
-
QIMR Berghofer says cell therapy saving lives of immunocompromised patients
December 11, 2024 - - Australian Biotech -
Welcome and encourage these workarounds because they expose the failing institution
December 11, 2024 - - Latest News -
FivepHusion secures ResectAssist platform technology for the localised delivery of cancer drugs
December 11, 2024 - - Latest News -
Budget update will reveal spending and revenue changes, including for the PBS
December 10, 2024 - - Latest News -
Pharmac seeks feedback on funding medicines for liver and ovarian cancer
December 10, 2024 - - Latest News -
Potential Australian developed treatment for MND shows positive early trial results
December 9, 2024 - - Australian Biotech -
TGA approves UCB therapy for the treatment of Dravet syndrome
December 9, 2024 - - Latest News